Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 25;8:762848. doi: 10.3389/fmed.2021.762848

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Shen, Lan, Zhu, Chen, Gu, Wang, Chen, Wang, Tu, Enghard, Jiang and Chen.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

ELISA validation and ROC analysis. (A) Serum IFI44 (Left) and IFIT3 (Right) were measured in 51 healthy controls and 73 LN patients by ELISA. (B) Receiver operator characteristic (ROC) curves show the diagnostic performance of serum IFI44 (blue) and IFIT3 (green) in identifying LN patients. (C) 73 LN patients were divided into two groups (Inactive LN=22, Active LN=51) according to renal biopsy and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). (D) ROC curves of IFI44, anti-dsDNA, C3, and C4 in differentiating active LN from inactive LN patients. (E) Serum IFI44 was tested in 12 healthy controls and 25 patients with IgA nephropathy. Data shown are mean ± SD by an unpaired t-test. *P < 0.05, **P < 0.01, ****P < 0.0001, ns, no significance; HC, healthy control; LN, lupus nephritis; IgAN, immunoglobulin A nephropathy.